Management of Spondyloarthropathy
| Autor: | Ruth Z. Lee, Douglas J. Veale |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
medicine.medical_specialty
Spondyloarthropathy Disease Receptors Tumor Necrosis Factor Etanercept medicine Humans Cyclooxygenase Inhibitors Pharmacology (medical) Spondylitis Randomized Controlled Trials as Topic Antibacterial agent Tumor Necrosis Factor-alpha business.industry Anti-Inflammatory Agents Non-Steroidal Sacroiliitis Enthesitis medicine.disease Dermatology Infliximab Immunoglobulin G Immunology Spondylarthropathies medicine.symptom business medicine.drug |
| Zdroj: | Drugs. 62:2349-2359 |
| ISSN: | 0012-6667 |
| DOI: | 10.2165/00003495-200262160-00003 |
| Popis: | Spondyloarthropathies (SpA) are a group of inflammatory arthritides classified according to common features of peripheral and spinal arthritis. The conventional anti-inflammatory and disease-modifying or slow-acting anti-rheumatic drugs do appear to be efficacious in treatment of the peripheral arthritis in a comparable fashion to seropositive rheumatoid arthritis, however, their efficacy in axial disease is unproven. This review examines new pharmacological developments in the treatment of SpA including the specific features of sacroiliitis, enthesitis and spondylitis in addition to the peripheral manifestations. The main points that are discussed are new cyclo-oxygenase (COX)-2 specific anti-inflammatories, biological therapies, such as anti-TNF compounds, and novel uses of well-known agents. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink